Psyber focuses on the development of brain-computer interface-enabled (BCI) digital therapeutics for treating mental health issues. On April 7th, 2021, ATAI Life Sciences acquired a majority stake in Psyber. The terms of the transaction were not disclosed.

We help leading organizations provide effective non-drug options for mental health

Big Health builds prescription digital treatments and programs to help providers treat mental health more effectively and efficiently. Today, our products address the three most common mental health conditions: sleep, anxiety, and depression. 

EEG-based BCI devices record electrical activity in the brain for real-time interpretation of emotional, behavioural, and mental states. Rationale: We believe in giving patients more power during their therapeutic journey, while both improving and enhancing their therapeutic experience. How it works: Psyber empowers patients who are prescribed medication to achieve better mental health outcomes by offering personalized digitally enhanced, behaviour-changing experiences that complement their medication assisted therapy. Objective: Better outcomes, a better experience and better personalized behaviour change training than existing medication or behavioral therapy solutions currently offer.